Home・Aktien・Pulmatrix Inc

Pulmatrix Inc

Geschlossen

1.61 -1.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.6

Max

1.62

Schlüsselkennzahlen
By Trading Economics
Einkommen	-244K -1.2M
EPS	-0.321
Angestellte	2
EBITDA	-244K -1.2M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.8M 6.4M
Vorheriger Eröffnungskurs	2.84
Vorheriger Schlusskurs	1.61

Pulmatrix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Aug. 2026, 23:51 UTC

U.S. Labor Market Contraction Fuels Stock Market Rally and Eases Fed Rate Hike Expectations

8. Aug. 2026, 23:51 UTC

U.S. equity markets surge to record highs as July job data signals potential pause in Federal Reserve interest rate hikes, while European stocks also reach all-time highs amid mixed economic signals.

8. Aug. 2026, 23:51 UTC

U.S. equity markets surge to record highs as disappointing July employment data shifts investor sentiment towards a potential pause in Federal Reserve interest rate hikes.

8. Aug. 2026, 23:51 UTC

U.S. equity markets surge as disappointing July jobs data lowers Fed rate hike expectations, with S&P500 hitting record high.

8. Aug. 2026, 23:51 UTC

US Producer Price Inflation Expected to Rise 0.1% in July Amid Labor Market Concerns and Fed Rate Speculations

8. Aug. 2026, 23:51 UTC

Correlated Moves

Macro News

Bitcoin trades higher as a surprising jobs report fuels speculation of interest rate cuts, potentially benefiting cryptocurrencies. Ethereum also sees a slight price increase.

8. Aug. 2026, 23:41 UTC

Core PPI Release on August 13, 2026, Expected to Show Moderate Inflation Increase Amid Mixed Labor Market Signals and Cautious Investor Sentiment.

8. Aug. 2026, 23:31 UTC

BoJ's Upcoming Summary of Opinions on August 9, 2026, May Signal Cautious Monetary Policy Amidst Mixed Market Sentiment and Global Rate Hike Discussions.

8. Aug. 2026, 23:21 UTC

Core Inflation Rate Expected at 2.5% Amid Mixed Economic Data and Job Losses, Influencing Fed's Interest Rate Decisions

8. Aug. 2026, 23:21 UTC

Core Inflation Rate Release on August 12, 2026 Expected to Show +0.2% Increase Amid Mixed Economic Signals and Job Market Concerns

8. Aug. 2026, 23:21 UTC

Investors Brace for July CPI Release Amid Mixed Employment Reports and Inflation Concerns Impacting Fed Policy Decisions

8. Aug. 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.1% in July Amid Mixed Economic Signals and Labor Market Concerns

8. Aug. 2026, 23:21 UTC

US CPI YoY Inflation Rate Expected at 3.4% Amid Mixed Economic Signals and Job Losses, Influencing Fed's Interest Rate Decisions

8. Aug. 2026, 23:21 UTC

Investors Brace for Volatility Ahead of August CPI Release Amid Mixed Economic Signals and Fed Rate Speculation

8. Aug. 2026, 23:11 UTC

Brazil's Retail Sales Report on August 13 Expected to Reveal Consumer Spending Trends Amid Economic Uncertainties.

8. Aug. 2026, 22:41 UTC

U.S. 30-Year Mortgage Rates Hit Year-High of 6.81% Amid Weak Job Growth and Fed Rate Speculation

8. Aug. 2026, 22:41 UTC

Cardano is trading lower today, continuing a downward trend since Friday. The asset remains above its 20-day moving average and near its one-month range high.

8. Aug. 2026, 22:31 UTC

Brazil's Inflation Rate MoM Release on August 11, 2026, Sparks Caution Among Analysts Amid Global Economic Uncertainties.

8. Aug. 2026, 22:31 UTC

Brazil's Inflation Rate Release on August 11, 2026 Expected to Reflect Moderate Trends Amid Global Economic Concerns.

8. Aug. 2026, 22:11 UTC

UK Housing Market Faces Caution Ahead of RICS House Price Balance Release Amid Stagnant Prices and Economic Uncertainty

8. Aug. 2026, 21:51 UTC

Japan's Current Account Surplus Forecasted at JPY 1,512 Billion Amid Forex Interventions and Cautious Market Sentiment Ahead of August Release.

8. Aug. 2026, 21:41 UTC

South Korea's unemployment rate expected to hold steady at 2.7% amid global economic uncertainties, with market sentiment cautiously optimistic ahead of August release.

8. Aug. 2026, 21:31 UTC

UK Retail Sales Monitor YoY for July 2026 Expected to Rise 1.5% Amid Mixed Sentiment and Economic Pressures

8. Aug. 2026, 21:21 UTC

India's July 2026 Inflation Rate Release Expected to Show Stability at 4.54% Amid Geopolitical Tensions and Food Price Pressures

8. Aug. 2026, 21:21 UTC

Brazil's Central Bank to announce interest rate decisions amid global economic uncertainties on August 10, 2026.

8. Aug. 2026, 20:31 UTC

Euro Area's Q2 Employment Change Data Release on August 14 Sparks Cautious Optimism Amid Rising Unemployment and Mixed Economic Signals.

8. Aug. 2026, 20:31 UTC

Euro Area Expected to Report €2.2 Billion Trade Deficit Amid Mixed Economic Signals and Rising Energy Costs

8. Aug. 2026, 20:31 UTC

China's Q2 2026 Current Account Data Release Expected to Show Continued Surplus Growth Amidst Global Economic Pressures

8. Aug. 2026, 20:11 UTC

Eurozone Industrial Production MoM data for June 2026 expected to show flat growth amid concerns over declining output and geopolitical tensions.

8. Aug. 2026, 20:01 UTC

South Africa's Q2 Unemployment Rate Set for Release Amidst Rising Global Job Concerns, Following Alarming 32.7% in Q1

Peer-Vergleich

Kursveränderung

Pulmatrix Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pulmatrix Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.